NDA 213716 · Aurinia
Lupkynis
Voclosporin · Oral · Calcineurin Inhibitor Immunosuppressant
NovelPriority reviewCDER novel approval, Jan 22, 2021: To treat lupus nephritis
Last checked: Nov 19, 2026Latest source record: Oct 8, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Jan 22, 2021
Approved uses
2
Original approval plus efficacy supplements
Registered trials
24
11 Phase 3, 5 recruiting
FAERS reports
9,788
1,987 serious, 61 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: MALIGNANCIES AND SERIOUS INFECTIONS Increased risk for developing malignancies and serious infections with LUPKYNIS or other immunosuppressants that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 , 5.2 )]. WARNING: MALIGNANCIES AND SERIOUS INFECTIONS See full prescribing information for complete boxed warning. Increased risk for developing serious infections and malignancies with LUPKYNIS or other immunosuppressants that may lead to hospitalization or death. ( 5.1 , 5.2 )
What it is approved for
From the label in effect Nov 11, 2026.
LUPKYNIS is indicated in combination with a background immunosuppressive therapy regimen [see Clinical Studies ( 14 )] for the treatment of adult patients with active lupus nephritis (LN). Limitations of Use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation. LUPKYNIS is a calcineurin-inhibitor immunosuppressant indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN). ( 1 , 14 ) Limitations of Use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation.
Mechanism: LUPKYNIS is a calcineurin-inhibitor immunosuppressant. The mechanism of voclosporin suppression of calcineurin has not been fully established. Activation of lymphocytes involves an increase in intracellular calcium concentrations that bind to the calcineurin regulatory site and activate calmodulin binding catalytic subunit and through dephosphorylation activates the transcription factor, Nuclear Factor of Activated T-Cell Cytoplasmic (NFATc). The immunosuppressant activity results in inhibition of lymphocyte proliferation, T-cell cytokine production, and expression of T-cell activation...
Therapeutic areas: Immunology and inflammation · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 29, 2024 Supplement 4 · Efficacy LetterLabel
- Jan 22, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
- LUPKYNIS · VOCLOSPORIN 7.9MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Voclosporin" as an intervention, any sponsor and status, largest first.
- Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis PatientsPivotal-lookingCompleted
Aurinia Pharmaceuticals Inc.Industry
NCT00408187 · 642 participants · Start Dec 2006 · Primary completion Dec 2008
Drug: voclosporin; Ciclosporin and 1 more · For: Psoriasis
Sites: Edmonton, Canada; Surrey, Canada; Vancouver, Canada · 49 sites in all
- Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye SyndromePivotal-lookingCompleted
Aurinia Pharmaceuticals Inc.Industry
NCT04147650 · 508 participants · Start Oct 14, 2019 · Primary completion Sep 17, 2020
Drug: 0.05% Voclosporin Ophthalmic Solution (VOS); 0.10% VOS and 2 more · For: Dry Eye Syndrome; Keratoconjunctivitis Sicca
Sites: Newport Beach, California; Colorado Springs, Colorado; Louisville, Kentucky · 9 sites in all
- Randomized Placebo-controlled Study of ISA247 in Plaque PsoriasisPivotal-lookingCompleted
Aurinia Pharmaceuticals Inc.Industry
NCT00244842 · 451 participants · Start Dec 2004 · Primary completion Oct 2005
Drug: voclosporin; Placebo · For: Psoriasis
Sites: Calgary, Canada; Edmonton, Canada; Vancouver, Canada · 31 sites in all
- Aurinia Renal Response in Active Lupus With VoclosporinPivotal-lookingCompleted
Aurinia Pharmaceuticals Inc.Industry
NCT03021499 · 358 participants · Start May 17, 2017 · Primary completion Sep 24, 2019
Drug: Voclosporin; Placebo Oral Capsule · For: Lupus Nephritis
Sites: Huntsville, Alabama; Phoenix, Arizona; Beverly Hills, California · 185 sites in all
- Study of ISA247 (Voclosporin) in De Novo Renal TransplantationPivotal-lookingCompleted
Aurinia Pharmaceuticals Inc.Industry
NCT00270634 · 334 participants · Start Jan 2006 · Primary completion Jul 2009
Drug: Voclosporin; tacrolimus · For: Kidney Diseases
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 45 sites in all
- A 36-Week Extension to Protocol ISA04-03Pivotal-lookingCompleted
Aurinia Pharmaceuticals Inc.Industry
NCT00258713 · 309 participants · Start Sep 2005 · Primary completion Jul 2006
Drug: voclosporin · For: Psoriasis
Sites: Calgary, Canada; Edmonton, Canada; Vancouver, Canada · 29 sites in all
- A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus NephritisPivotal-lookingRecruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT06406205 · 270 participants (planned) · Start Dec 25, 2023 · Primary completion Jun 2027
Drug: Voclosporin(QL1074); Placebo · For: Lupus Nephritis
Sites: Bengbu, China; Bozhou, China; Hefei, China · 10 sites in all
- AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)Pivotal-lookingCompleted
Aurinia Pharmaceuticals Inc.Industry
NCT02141672 · 265 participants · Start Jun 2014 · Primary completion Jul 2016
Drug: Voclosporin High Dose; Voclosporin Low Dose and 1 more · For: Lupus Nephritis
Sites: Los Angeles, California; Palo Alto, California; Gainesville, Florida · 86 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- therapy interrupted991
- product dose omission issue870
- hypertension807
- headache764
- nausea715
- fatigue625
- diarrhoea605
- proteinuria557
- blood pressure increased440
- product use issue427
- glomerular filtration rate decreased380
- vomiting369
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2021 | 431 |
| 2022 | 1,006 |
| 2023 | 1,506 |
| 2024 | 2,002 |
| 2025 | 2,316 |
| 2026 | 2,526 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lupkynis (Voclosporin)
2024 spending
$25.8M
Beneficiaries
339
2,078 claims
Per beneficiary
$75,988
$81.70 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $4,067,190 |
| 2022 | $12,639,888 |
| 2023 | $20,169,855 |
| 2024 | $25,759,784 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Rovin BH, Teng YKO, Ginzler EM, et al. · Lancet 2021 · Clinical Trial, Phase III, Multicenter Study
- Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations.
Kostopoulou M, Mukhtyar CB, Bertsias G, et al. · Ann Rheum Dis 2024 · Systematic Review
- Efficacy of Voclosporin in Proliferative Lupus Nephritis with High Levels of Proteinuria.
Menn-Josephy H, Hodge LS, Birardi V, et al. · Clin J Am Soc Nephrol 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.
Rovin BH, Solomons N, Pendergraft WF, et al. · Kidney Int 2019 · Clinical Trial, Phase II, Comparative Study
- Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis.
Jiang N, Jin S, Yu C, et al. · Front Immunol 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Effect of Long-Term Voclosporin Treatment on Renal Histology in Patients With Active Lupus Nephritis With Repeat Renal Biopsies.
Rovin BH, Cassol C, Parikh SV, et al. · Arthritis Rheumatol 2025 · Randomized Controlled Trial
Sponsor: Aurinia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.